Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

(Alliance News) - Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour cell DNA workflow, using Illumina Inc's sequencing technology for ...

Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

From 1990 to 2019, global lung cancer mortality rates related to tobacco have gone down, whereas rates related to ambient ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Lung cancer remains the leading cause of cancer-related deaths globally, with cigarette smoking as its primary driver.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.